25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

8AT (Aclaris Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aclaris Therapeutics Inc together

I guess you are interested in Aclaris Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Aclaris Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Aclaris Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Aclaris Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aclaris Therapeutics Inc

I send you an email if I find something interesting about Aclaris Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aclaris Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aclaris Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.34
Expected worth in 1 year
€0.64
How sure are you?
21.4%

+ What do you gain per year?

Total Gains per Share
€-0.70
Return On Investment
-50.0%

For what price can you sell your share?

Current Price per Share
€1.41
Expected price per share
€1.1215 - €2.211
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aclaris Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
€1.41
Intrinsic Value Per Share
€-12.23 - €-14.36
Total Value Per Share
€-10.89 - €-13.03

2.2. Growth of Aclaris Therapeutics Inc (5 min.)




Is Aclaris Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$155.5m$167.5m-$27.1m-19.3%

How much money is Aclaris Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$33m-$22.1m-$10.8m-33.0%
Net Profit Margin-581.6%-754.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Aclaris Therapeutics Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aclaris Therapeutics Inc?

Welcome investor! Aclaris Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aclaris Therapeutics Inc.

First you should know what it really means to hold a share of Aclaris Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aclaris Therapeutics Inc is €1.408. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aclaris Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aclaris Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.34. Based on the TTM, the Book Value Change Per Share is €-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aclaris Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.90-64.1%-0.35-24.9%-0.32-22.6%-0.34-23.9%-0.34-23.9%
Usd Book Value Change Per Share-0.37-26.2%-0.19-13.6%-0.19-13.2%0.107.4%0.107.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.37-26.2%-0.19-13.6%-0.19-13.2%0.107.4%0.107.4%
Usd Price Per Share2.80-1.56-6.56-9.03-9.03-
Price to Earnings Ratio-0.78--1.61--6.86--7.43--7.43-
Price-to-Total Gains Ratio-7.60--10.74--12.26--19.95--19.95-
Price to Book Ratio1.93-0.93-2.68-3.12-3.12-
Price-to-Total Gains Ratio-7.60--10.74--12.26--19.95--19.95-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.528384
Number of shares654
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.190.10
Usd Total Gains Per Share-0.190.10
Gains per Quarter (654 shares)-124.8467.90
Gains per Year (654 shares)-499.34271.59
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-499-5090272262
20-999-10080543534
30-1498-15070815806
40-1997-2006010861078
50-2497-2505013581350
60-2996-3004016301622
70-3495-3503019011894
80-3995-4002021732166
90-4494-4501024442438
100-4993-5000027162710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.014.00.00.0%0.014.00.00.0%0.014.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.011.00.021.4%3.011.00.021.4%3.011.00.021.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.014.00.0%0.00.014.00.0%0.00.014.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.011.00.021.4%3.011.00.021.4%3.011.00.021.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aclaris Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.340-0.176-48%-0.172-49%0.096-455%0.096-455%
Book Value Per Share--1.3391.646-19%2.210-39%2.383-44%2.383-44%
Current Ratio--3.9866.315-37%6.147-35%8.661-54%8.661-54%
Debt To Asset Ratio--0.2940.233+26%0.239+23%0.217+35%0.217+35%
Debt To Equity Ratio--0.4160.312+34%0.316+32%0.282+48%0.282+48%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--216867523.64084825523.519+156%372878539.024-42%507318038.420-57%507318038.420-57%
Eps---0.831-0.322-61%-0.293-65%-0.310-63%-0.310-63%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--6.3904.578+40%37.397-83%58.135-89%58.135-89%
Free Cash Flow Per Share---0.385-0.133-66%-0.264-32%-0.212-45%-0.212-45%
Free Cash Flow To Equity Per Share--0.2570.028+832%-0.177+169%-0.082+132%-0.082+132%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---14.365--------
Intrinsic Value_10Y_min---12.232--------
Intrinsic Value_1Y_max---0.937--------
Intrinsic Value_1Y_min---0.920--------
Intrinsic Value_3Y_max---3.198--------
Intrinsic Value_3Y_min---3.046--------
Intrinsic Value_5Y_max---5.921--------
Intrinsic Value_5Y_min---5.463--------
Market Cap--276536411.240125431098.319+120%421481281.324-34%552158172.220-50%552158172.220-50%
Net Profit Margin---10.482-5.816-45%-7.549-28%-8.027-23%-8.027-23%
Operating Margin----0%-0%-0%-0%
Operating Ratio--3.5375.519-36%10.202-65%9.395-62%9.395-62%
Pb Ratio1.052-84%1.9300.934+107%2.675-28%3.115-38%3.115-38%
Pe Ratio-0.424+46%-0.777-1.611+107%-6.862+783%-7.426+855%-7.426+855%
Price Per Share1.408-84%2.5841.435+80%6.048-57%8.322-69%8.322-69%
Price To Free Cash Flow Ratio-0.914+46%-1.677-0.861-49%-5.307+216%-9.494+466%-9.494+466%
Price To Total Gains Ratio-4.144+46%-7.604-10.738+41%-12.262+61%-19.952+162%-19.952+162%
Quick Ratio--2.8284.342-35%3.942-28%6.110-54%6.110-54%
Return On Assets---0.438-0.161-63%-0.097-78%-0.110-75%-0.110-75%
Return On Equity---0.621-0.220-65%-0.130-79%-0.145-77%-0.145-77%
Total Gains Per Share---0.340-0.176-48%-0.172-49%0.096-455%0.096-455%
Usd Book Value--155548182.280140379999.592+11%167511734.827-7%177060877.676-12%177060877.676-12%
Usd Book Value Change Per Share---0.369-0.191-48%-0.187-49%0.104-455%0.104-455%
Usd Book Value Per Share--1.4531.786-19%2.399-39%2.587-44%2.587-44%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--235409696.91192078105.780+156%404759654.110-42%550693730.705-57%550693730.705-57%
Usd Eps---0.902-0.350-61%-0.318-65%-0.337-63%-0.337-63%
Usd Free Cash Flow---44746326.425-14000976.344-69%-19907755.422-56%-16552880.899-63%-16552880.899-63%
Usd Free Cash Flow Per Share---0.418-0.144-66%-0.286-32%-0.230-45%-0.230-45%
Usd Free Cash Flow To Equity Per Share--0.2790.030+832%-0.192+169%-0.089+132%-0.089+132%
Usd Market Cap--300180274.401136155457.226+120%457517930.877-34%599367695.945-50%599367695.945-50%
Usd Price Per Share1.528-84%2.8051.558+80%6.565-57%9.033-69%9.033-69%
Usd Profit---96548388.955-33015015.192-66%-22119422.703-77%-25099346.964-74%-25099346.964-74%
Usd Revenue--9210655.5094680074.959+97%7811957.822+18%5919921.444+56%5919921.444+56%
Usd Total Gains Per Share---0.369-0.191-48%-0.187-49%0.104-455%0.104-455%
 EOD+3 -3MRQTTM+13 -22YOY+7 -285Y+7 -2810Y+7 -28

3.3 Fundamental Score

Let's check the fundamental score of Aclaris Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.424
Price to Book Ratio (EOD)Between0-11.052
Net Profit Margin (MRQ)Greater than0-10.482
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.828
Current Ratio (MRQ)Greater than13.986
Debt to Asset Ratio (MRQ)Less than10.294
Debt to Equity Ratio (MRQ)Less than10.416
Return on Equity (MRQ)Greater than0.15-0.621
Return on Assets (MRQ)Greater than0.05-0.438
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Aclaris Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5017.474
Ma 20Greater thanMa 501.831
Ma 50Greater thanMa 1002.132
Ma 100Greater thanMa 2002.406
OpenGreater thanClose1.405
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Aclaris Therapeutics Inc

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Aclaris Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • A Net Profit Margin of -1,048.2%Β means thatΒ €-10.48 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aclaris Therapeutics Inc:

  • The MRQ is -1,048.2%. The company is making a huge loss. -2
  • The TTM is -581.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,048.2%TTM-581.6%-466.6%
TTM-581.6%YOY-754.9%+173.3%
TTM-581.6%5Y-802.7%+221.1%
5Y-802.7%10Y-802.7%0.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Aclaris Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • -43.8% Return on Assets means thatΒ Aclaris Therapeutics Inc generatedΒ €-0.44 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aclaris Therapeutics Inc:

  • The MRQ is -43.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-43.8%TTM-16.1%-27.7%
TTM-16.1%YOY-9.7%-6.4%
TTM-16.1%5Y-11.0%-5.1%
5Y-11.0%10Y-11.0%0.0%
4.3.1.3. Return on Equity

Shows how efficient Aclaris Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • -62.1% Return on Equity means Aclaris Therapeutics Inc generated €-0.62Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aclaris Therapeutics Inc:

  • The MRQ is -62.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-62.1%TTM-22.0%-40.1%
TTM-22.0%YOY-13.0%-9.0%
TTM-22.0%5Y-14.5%-7.5%
5Y-14.5%10Y-14.5%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aclaris Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Aclaris Therapeutics Inc is operatingΒ .

  • Measures how much profit Aclaris Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Aclaris Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ  industry mean).
  • An Operation Ratio of 3.54 means that the operating costs are €3.54 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 3.537. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.519. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.537TTM5.519-1.982
TTM5.519YOY10.202-4.683
TTM5.5195Y9.395-3.876
5Y9.39510Y9.3950.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aclaris Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ  industry mean).
  • A Current Ratio of 3.99Β means the company has €3.99 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 3.986. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.315. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.986TTM6.315-2.329
TTM6.315YOY6.147+0.168
TTM6.3155Y8.661-2.346
5Y8.66110Y8.6610.000
4.4.3.2. Quick Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • A Quick Ratio of 2.83Β means the company can pay off €2.83 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 2.828. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.342. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.828TTM4.342-1.514
TTM4.342YOY3.942+0.399
TTM4.3425Y6.110-1.768
5Y6.11010Y6.1100.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aclaris Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Aclaris Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Aclaris Therapeutics Inc to industry mean.
  • A Debt to Asset Ratio of 0.29Β means that Aclaris Therapeutics Inc assets areΒ financed with 29.4% credit (debt) and the remaining percentage (100% - 29.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.294. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.233. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.294TTM0.233+0.061
TTM0.233YOY0.239-0.005
TTM0.2335Y0.217+0.016
5Y0.21710Y0.2170.000
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Aclaris Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • A Debt to Equity ratio of 41.6% means that company has €0.42 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.416. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.312. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.416TTM0.312+0.105
TTM0.312YOY0.316-0.004
TTM0.3125Y0.282+0.030
5Y0.28210Y0.2820.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Aclaris Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Aclaris Therapeutics Inc to theΒ  industry mean.
  • A PE ratio of -0.78 means the investor is paying €-0.78Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is -0.424. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.777. Based on the earnings, the company is expensive. -2
  • The TTM is -1.611. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.424MRQ-0.777+0.354
MRQ-0.777TTM-1.611+0.833
TTM-1.611YOY-6.862+5.251
TTM-1.6115Y-7.426+5.815
5Y-7.42610Y-7.4260.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is -0.914. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.677. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.861. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.914MRQ-1.677+0.763
MRQ-1.677TTM-0.861-0.816
TTM-0.861YOY-5.307+4.446
TTM-0.8615Y-9.494+8.633
5Y-9.49410Y-9.4940.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Aclaris Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to industry mean).
  • A PB ratio of 1.93 means the investor is paying €1.93Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is 1.052. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.930. Based on the equity, the company is underpriced. +1
  • The TTM is 0.934. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.052MRQ1.930-0.878
MRQ1.930TTM0.934+0.996
TTM0.934YOY2.675-1.741
TTM0.9345Y3.115-2.181
5Y3.11510Y3.1150.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Gross Profit  10,264-9,7505142757899961,785-1,868-83



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets220,327
Total Liabilities64,773
Total Stockholder Equity155,554
 As reported
Total Liabilities 64,773
Total Stockholder Equity+ 155,554
Total Assets = 220,327

Assets

Total Assets220,327
Total Current Assets125,951
Long-term Assets94,376
Total Current Assets
Cash And Cash Equivalents 24,570
Short-term Investments 89,024
Net Receivables 318
Other Current Assets 12,039
Total Current Assets  (as reported)125,951
Total Current Assets  (calculated)125,951
+/-0
Long-term Assets
Property Plant Equipment 1,008
Long Term Investments 90,302
Long-term Assets Other 3,066
Long-term Assets  (as reported)94,376
Long-term Assets  (calculated)94,376
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities31,596
Long-term Liabilities33,177
Total Stockholder Equity155,554
Total Current Liabilities
Accounts payable 4,690
Other Current Liabilities 2,683
Total Current Liabilities  (as reported)31,596
Total Current Liabilities  (calculated)7,373
+/- 24,223
Long-term Liabilities
Long-term Liabilities Other 13,139
Long-term Liabilities  (as reported)33,177
Long-term Liabilities  (calculated)13,139
+/- 20,038
Total Stockholder Equity
Total Stockholder Equity (as reported)155,554
Total Stockholder Equity (calculated)0
+/- 155,554
Other
Capital Stock1
Common Stock Shares Outstanding 107,019
Net Invested Capital 155,554
Net Working Capital 94,355
Property Plant and Equipment Gross 5,813



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
263,494
251,211
226,527
277,976
267,632
254,596
229,705
235,649
218,354
197,405
174,065
161,071
182,394
220,327
220,327182,394161,071174,065197,405218,354235,649229,705254,596267,632277,976226,527251,211263,494
   > Total Current Assets 
205,782
205,032
190,881
259,354
256,573
231,550
184,361
132,935
123,068
128,856
135,338
117,635
132,330
125,951
125,951132,330117,635135,338128,856123,068132,935184,361231,550256,573259,354190,881205,032205,782
       Cash And Cash Equivalents 
53,602
27,349
36,342
68,264
61,653
45,277
44,722
31,150
39,040
39,878
35,841
22,834
47,651
24,570
24,57047,65122,83435,84139,87839,04031,15044,72245,27761,65368,26436,34227,34953,602
       Short-term Investments 
144,280
164,065
143,280
180,339
186,409
172,294
126,081
88,625
64,012
79,228
92,325
88,259
80,071
89,024
89,02480,07188,25992,32579,22864,01288,625126,081172,294186,409180,339143,280164,065144,280
       Net Receivables 
811
623
633
637
597
484
686
431
346
298
373
325
343
318
318343325373298346431686484597637633623811
       Other Current Assets 
0
12,995
10,626
10,114
7,914
13,495
12,872
12,729
19,670
9,452
6,799
6,217
4,265
12,039
12,0394,2656,2176,7999,45219,67012,72912,87213,4957,91410,11410,62612,9950
   > Long-term Assets 
57,712
46,179
35,646
18,622
11,059
23,046
45,344
102,714
95,286
68,549
38,727
43,436
50,064
94,376
94,37650,06443,43638,72768,54995,286102,71445,34423,04611,05918,62235,64646,17957,712
       Property Plant Equipment 
0
0
0
0
1,145
1,099
1,513
1,899
1,764
1,620
1,531
1,293
1,133
1,008
1,0081,1331,2931,5311,6201,7641,8991,5131,0991,1450000
       Long Term Investments 
45,735
34,242
23,955
7,221
0
12,242
33,602
90,992
83,944
62,771
33,199
38,778
45,714
90,302
90,30245,71438,77833,19962,77183,94490,99233,60212,24207,22123,95534,24245,735
       Intangible Assets 
7,067
7,048
7,030
7,011
6,992
6,973
6,954
6,935
6,917
269
0
0
0
0
00002696,9176,9356,9546,9736,9927,0117,0307,0487,067
       Long-term Assets Other 
3,740
3,554
3,384
3,114
2,922
2,732
3,275
2,888
2,661
3,889
3,997
3,365
3,217
3,066
3,0663,2173,3653,9973,8892,6612,8883,2752,7322,9223,1143,3843,5543,740
> Total Liabilities 
46,913
53,870
46,328
42,224
47,794
56,975
52,895
55,899
62,021
40,226
32,051
27,249
52,243
64,773
64,77352,24327,24932,05140,22662,02155,89952,89556,97547,79442,22446,32853,87046,913
   > Total Current Liabilities 
17,839
22,931
16,726
16,217
19,789
21,938
18,258
22,829
27,320
30,952
20,080
15,682
18,816
31,596
31,59618,81615,68220,08030,95227,32022,82918,25821,93819,78916,21716,72622,93117,839
       Accounts payable 
7,564
9,985
8,121
5,703
7,667
10,351
8,190
11,425
9,648
8,878
10,810
7,269
7,662
4,690
4,6907,6627,26910,8108,8789,64811,4258,19010,3517,6675,7038,1219,9857,564
       Other Current Liabilities 
2,198
2,202
2,202
2,202
2,202
2,202
2,202
2,202
2,202
2,202
2,705
2,651
2,667
2,683
2,6832,6672,6512,7052,2022,2022,2022,2022,2022,2022,2022,2022,2022,198
   > Long-term Liabilities 
29,074
30,939
29,602
26,007
28,005
35,037
34,637
33,070
34,701
9,274
11,971
11,567
33,427
33,177
33,17733,42711,56711,9719,27434,70133,07034,63735,03728,00526,00729,60230,93929,074
       Capital Lease Obligations Min Short Term Debt
669
693
716
741
766
684
603
458
310
426
0
0
0
0
0000426310458603684766741716693669
       Long-term Liabilities Other 
28,707
30,572
29,235
25,640
27,638
34,670
34,270
32,703
34,334
9,274
11,971
11,567
12,245
13,139
13,13912,24511,56711,9719,27434,33432,70334,27034,67027,63825,64029,23530,57228,707
> Total Stockholder Equity
216,581
197,341
180,199
235,752
219,838
197,621
176,810
179,750
156,333
157,179
142,014
133,822
130,151
155,554
155,554130,151133,822142,014157,179156,333179,750176,810197,621219,838235,752180,199197,341216,581
   Common Stock00000000000000
   Retained Earnings Total Equity00000000000000
   Accumulated Other Comprehensive Income 00000000000000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 00000000000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue18,720
Cost of Revenue-15,458
Gross Profit3,2623,262
 
Operating Income (+$)
Gross Profit3,262
Operating Expense-71,247
Operating Income-52,527-67,985
 
Operating Expense (+$)
Research Development33,586
Selling General Administrative22,203
Selling And Marketing Expenses-
Operating Expense71,24755,789
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income-52,527
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-132,06527,011
EBIT - interestExpense = 0
-132,065
-132,065
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--132,065
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-132,065
Tax Provision-0
Net Income From Continuing Ops-132,065-132,065
Net Income-132,065
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-79,5380
 

Technical Analysis of Aclaris Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aclaris Therapeutics Inc. The general trend of Aclaris Therapeutics Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aclaris Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aclaris Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aclaris Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.916 < 2.062 < 2.211.

The bearish price targets are: 1.34 > 1.3 > 1.1215.

Tweet this
Aclaris Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aclaris Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aclaris Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aclaris Therapeutics Inc. The current macd is -0.21809143.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aclaris Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aclaris Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aclaris Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aclaris Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAclaris Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aclaris Therapeutics Inc. The current adx is 46.24.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aclaris Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Aclaris Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aclaris Therapeutics Inc. The current sar is 1.61899938.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aclaris Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aclaris Therapeutics Inc. The current rsi is 17.47. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Aclaris Therapeutics Inc Daily Relative Strength Index (RSI) ChartAclaris Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aclaris Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aclaris Therapeutics Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Aclaris Therapeutics Inc Daily Stochastic Oscillator ChartAclaris Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aclaris Therapeutics Inc. The current cci is -124.93527764.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Aclaris Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAclaris Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aclaris Therapeutics Inc. The current cmo is -79.53997344.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aclaris Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAclaris Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aclaris Therapeutics Inc. The current willr is -99.4011976.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Aclaris Therapeutics Inc Daily Williams %R ChartAclaris Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aclaris Therapeutics Inc. The current atr is 0.06933265.

Aclaris Therapeutics Inc Daily Average True Range (ATR) ChartAclaris Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aclaris Therapeutics Inc. The current obv is 2,884.

Aclaris Therapeutics Inc Daily On-Balance Volume (OBV) ChartAclaris Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aclaris Therapeutics Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aclaris Therapeutics Inc Daily Money Flow Index (MFI) ChartAclaris Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aclaris Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Aclaris Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aclaris Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5017.474
Ma 20Greater thanMa 501.831
Ma 50Greater thanMa 1002.132
Ma 100Greater thanMa 2002.406
OpenGreater thanClose1.405
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aclaris Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Aclaris Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aclaris Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aclaris Therapeutics Inc

I send you an email if I find something interesting about Aclaris Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aclaris Therapeutics Inc.

Receive notifications about Aclaris Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.